Hong Kong Pharma Digital Technology Holdings Ltd
HKPD$7M
Micro CapNASDAQWholesale-Drugs, Proprietaries & Druggists' Sundries🇺🇸North AmericaKOWLOON27 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Mar 15, 2026
11dMarket Overview
Stock performance and key metrics
HKPD News
Catalyst Timeline
2 upcoming, 0 past
Phase 2Next
EI-1071 tablet, oral Phase 2 Results Expected
March 2026~EstimatedEI-1071 tablet, oral15
Primary completion for EI-1071 tablet, oral trial (NCT06745583) in Mild, Moderate, or Severe Alzheimer's Disease
Source1 more catalyst beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Drug Pipeline
EI-001
Non-segmental Vitiligo
INS018_055
Idiopathic Pulmonary Fibrosis (IPF)
EI-1071 tablet, oral
Mild, Moderate, or Severe Alzheimer's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EI-001 | Phase 2 | Non-segmental Vitiligo | - | - |
INS018_055 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
EI-1071 tablet, oral | Phase 2 | Mild, Moderate, or Severe Alzheimer's Disease | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply